Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.

Ena J, Leach A, Nguyen P.

HIV Med. 2008 Oct;9(9):747-56. doi: 10.1111/j.1468-1293.2008.00627.x. Epub 2008 Jul 21. Review.

2.

Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.

Barreiro P, García-Benayas T, Soriano V, Gallant J.

AIDS Rev. 2002 Oct-Dec;4(4):233-41. Review.

PMID:
12555697
3.
4.

The role of nevirapine in the treatment of HIV-1 disease.

Podzamczer D, Fumero E.

Expert Opin Pharmacother. 2001 Dec;2(12):2065-78. Review.

PMID:
11825335
5.

Impact of nevirapine on lipid metabolism.

Clotet B, van der Valk M, Negredo E, Reiss P.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S79-84. Review.

PMID:
14562862
6.

Efficacy and durability of nevirapine in antiretroviral-experienced patients.

Harris M.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S53-8. Review.

PMID:
14562858
7.

Switch studies: a review.

Murphy RL, Smith WJ.

HIV Med. 2002 Apr;3(2):146-55. Review.

8.

Nevirapine in the treatment of HIV.

Milinkovic A, Martínez E.

Expert Rev Anti Infect Ther. 2004 Jun;2(3):367-73. Review.

PMID:
15482202
9.

Evaluation of nevirapine-switch strategies for HIV treatment.

Cooper CL.

HIV Med. 2006 Nov;7(8):537-43. Review.

10.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida..

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
11.

Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.

Kawalec P, Kryst J, Mikrut A, Pilc A.

PLoS One. 2013 Oct 7;8(10):e76587. doi: 10.1371/journal.pone.0076587. eCollection 2013. Review.

12.
13.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA.

AIDS. 2009 Jan 28;23(3):279-91. doi: 10.1097/QAD.0b013e32831c54e5. Review.

PMID:
19114854
14.

Contemporary role of nevirapine in HIV treatment.

Coster LO, Kumar PN.

AIDS Rev. 2012 Apr-Jun;14(2):132-44. Review.

PMID:
22627609
15.

Protease inhibitor-based regimens for HIV therapy: safety and efficacy.

Walmsley S.

J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S5-13; quiz S28-31. Review.

PMID:
17525691
16.

Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.

Bucher HC, Young J, Battegay M.

J Antimicrob Chemother. 2004 Aug;54(2):303-5. Epub 2004 Jul 21. Review.

PMID:
15269200
17.

Risk for immune-mediated liver reactions by nevirapine revisited.

Medrano J, Barreiro P, Tuma P, Vispo E, Labarga P, Blanco F, Soriano V.

AIDS Rev. 2008 Apr-Jun;10(2):110-5. Review.

PMID:
18615121
18.

Guidelines for the use of extended-release nevirapine in HIV-infected patients.

Heil EL, Corbett AH.

Expert Opin Pharmacother. 2011 Dec;12(17):2713-8. doi: 10.1517/14656566.2011.630391. Epub 2011 Oct 29. Review.

PMID:
22035406
19.

Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods.

Journot V, Chêne G, Joly P, Savès M, Jacqmin-Gadda H, Molina JM, Salamon R; ALBI Study Group..

Control Clin Trials. 2001 Dec;22(6):639-58. Review.

PMID:
11738121
20.

Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, Vernazza P, Cahn P, Meynard JL, Arribas J, Bucher HC.

PLoS One. 2011;6(7):e22003. doi: 10.1371/journal.pone.0022003. Epub 2011 Jul 19. Review.

Supplemental Content

Support Center